bioAffinity Technologies, Inc. (BIAF) has faced a significant setback, with its shares dropping 77% over the past three months, while the biotechnology industry has seen a modest rise of 4.5%. The company’s financial struggles include a wider net loss due to increased commercialization and clinical development costs, despite strong year-over-year growth of over 200% in commercial sales for its product, CyPath Lung, reported in July.
For the first quarter of 2026, BIAF experienced a decline in total revenues, exacerbated by the strategic discontinuation of lower-margin services. The company is currently reliant on equity financing, as it progresses through early-stage commercialization. CyPath Lung remains its only commercial product, illustrating a concentrated business model vulnerable to regulatory changes and market acceptance.
Despite these challenges, bioAffinity’s management is focusing on increasing physician adoption and expanding its testing footprint, expecting broader awareness to boost growth through 2026. Financial indicators show that BIAF’s trailing 12-month price-to-book ratio is 1.02, much lower than the industry average of 3.65, indicating potential for future growth if it overcomes its operational hurdles.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
